For the year ending 2025-12-31, UNCY had $3,056K increase in cash & cash equivalents over the period. -$31,341K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,555 |
| Depreciation expense | 34 |
| Stock-based compensation expense | 2,641 |
| Change in fair value of warrant liability | -2,021 |
| Amortization of operating lease right of use asset | 538 |
| Prepaid expense and other current assets | 2,884 |
| Accounts payable and accrued liabilities | -2,505 |
| Operating lease liability | -565 |
| Net cash used in operating activities | -31,317 |
| Purchases of marketable securities | 12,071 |
| Purchases of property and equipment | 24 |
| Net cash used in investing activities | -12,095 |
| Gross proceeds from secondary public offering | 46,582 |
| Commissions paid on secondary public offering | 1,398 |
| Payments on financed insurance policies | 212 |
| Proceeds from exercise of warrants | 1,496 |
| Net cash provided by financing activities | 46,468 |
| Net increase in cash and cash equivalents | 3,056 |
| Cash and cash equivalents at the beginning of the period | 26,142 |
| Cash and cash equivalents at the end of the period | 29,198 |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)